Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response.
about
Discovery of Innovative Therapies for Rare Immune-Mediated Inflammatory Diseases via Off-Label Prescription of Biologics: The Case of IL-6 Receptor Blockade in Castleman's DiseaseThe Interplay Between Monocytes/Macrophages and CD4(+) T Cell Subsets in Rheumatoid ArthritisMolecular targets in arthritis and recent trends in nanotherapyThe balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritisNew Directions in the Treatment of Chronic Pain: National Pain Strategy Will Guide Prevention, Management, and Research.Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis.Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational studyProtective effect of taraxasterol against rheumatoid arthritis by the modulation of inflammatory responses in miceLymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?The role and therapeutic targeting of IL-6 in rheumatoid arthritis.Targeting the Monocyte-Macrophage Lineage in Solid Organ TransplantationFoxP3 Expression in Macrophages, Cancer, and B Cells-Is It Real?Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis.Immunophenotyping of rheumatoid arthritis reveals a linkage between HLA-DRB1 genotype, CXCR4 expression on memory CD4(+) T cells, and disease activity.Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?Leveraging blood and tissue CD4+ T cell heterogeneity at the single cell level to identify mechanisms of disease in rheumatoid arthritis.T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy.Treatment of rheumatoid arthritis with biological agents - as a typical and common immune-mediated inflammatory disease.Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial.Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.The Balance of Th17 versus Treg Cells in Autoimmunity.
P2860
Q26772331-E3DB30EC-5565-4E4A-9223-F64354EDD18CQ26774681-77143438-94E0-4889-B477-847B949B5B5BQ26783466-CF36ABE0-C8DA-406E-83AB-5416E778CF4AQ36078964-6C0C8B9A-A082-48B6-AFB6-5C5EDF1DEC0DQ36557004-DF50863A-2DBD-4CA6-862F-39BD3C5D4350Q37036028-E823B6E1-2FCC-48C6-A00C-67E8B3B2C243Q37111423-2A874080-E489-4A4E-9F3D-83350DEED3E1Q37581950-1F07851B-F49D-4692-A51B-7BD67D4C32D7Q38676903-B9A1EFEC-58F0-4FD2-885C-9BE84CF8956EQ38685086-C567BCC3-FD79-4EB1-9CD5-68717016790DQ38750505-9F7E8CC5-E689-4E86-9068-216FC1F02935Q38875380-911CE5D6-43A7-45AE-A84A-4F87ED20DE62Q39015080-16A0BF42-070D-431E-BB67-1633B9FF0B2AQ41500669-B08DE355-A1C4-417C-9EE4-71AD0F9112ACQ42071582-B3ED1FC9-B4FE-418F-AE09-40200B350BC9Q42633541-0CE830E3-644D-43D4-9BA3-D34B31D92714Q42777634-FE2708CC-9EFC-4FA9-9FA2-28CC1CD4F2B4Q47131694-9F14FAF6-3558-4CBA-BCE2-DA5151B1E266Q47163453-637D4731-27FE-4A76-9640-FE49C854A049Q50700806-674A5283-816D-4CB0-A2D4-AE422DB5328EQ53504304-28BEBB36-491B-4DF4-BFA3-AEF9AA47A25AQ55314022-4113B046-4038-41A5-B7DB-608089CB2485
P2860
Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Peripheral blood CD4(+)CD25(+) ...... elates with clinical response.
@ast
Peripheral blood CD4(+)CD25(+) ...... elates with clinical response.
@en
type
label
Peripheral blood CD4(+)CD25(+) ...... elates with clinical response.
@ast
Peripheral blood CD4(+)CD25(+) ...... elates with clinical response.
@en
prefLabel
Peripheral blood CD4(+)CD25(+) ...... elates with clinical response.
@ast
Peripheral blood CD4(+)CD25(+) ...... elates with clinical response.
@en
P2093
P2860
P1476
Peripheral blood CD4(+)CD25(+) ...... relates with clinical response
@en
P2093
Jun Kikuchi
Keiko Yoshimoto
Misato Hashizume
Naoshi Nishina
Yuko Kaneko
P2860
P2888
P356
10.1186/S13075-015-0526-4
P577
2015-01-21T00:00:00Z
P5875
P6179
1040168264